Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods for treatment of type vii collagen deficiencies

A technology of collagen and lentiviral vectors, applied in biochemical equipment and methods, drug combinations, and the use of vectors to introduce foreign genetic materials, etc., can solve problems such as no priority integration

Pending Publication Date: 2019-01-22
INTREXON CORP (US)
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Safety studies from clinical trials of gene therapy using LV vectors show no preferential integration in or near proto-oncogenes or tumor suppressor genes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of type vii collagen deficiencies
  • Compositions and methods for treatment of type vii collagen deficiencies
  • Compositions and methods for treatment of type vii collagen deficiencies

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0134] A. Illustration of the structure and characterization of FCX-007 transduced with the lentiviral vector INXN-2002

[0135] FCX-007 cells derived from the lentiviral vector INXN-2002 cells were suspended in a cryopreservation medium consisting of Iscove's Modified Dulbecco's Medium (IMDM) without fetal bovine serum (50.0% ), Profreeze-CDMTM (42.5%) and dimethylsulfoxide (DMSO) (7.5%). The structural characterization of FCX-007 drug product (DS) includes the primary structure of autologous human dermal fibroblasts (HDF) and the structure of the lentiviral vector used to transduce and genetically modify HDF cells.

[0136] B. Lentiviral vector (INXN-2002)

[0137] The INXN-2002 lentiviral vector (LV) used to transduce and introduce human collagen 7A1 gene into HDF cells is a recombinant lentiviral vector encoding human collagen 7A1 gene. INXN-2002 LV is a self-inactivating (SIN) lentiviral vector constructed based on human immunodeficiency virus type 1 (HIV-1) pseudotyped...

example 2

[0188] Example 2: FCX-007 transduced with INXN-2004 lentiviral vector

[0189]FCX-007 is an autologous fibroblast product genetically modified by the INXN-2004 lentiviral vector (LV-COL7) to express human collagen 7 protein (C7). The materials described below for the production of FCX-007 DS / INXN-2004 were similar to those described above in Example 1, except that the IGE-230 LV-COL7 vector plasmid was used to produce INXN-2002. The IGE-308 LV-COL7 vector plasmid was used to prepare the INXN-2004 vector. The 293 WCB cell line was co-transfected with the same helper plasmids pCMV-G, pCMV-Rev2 and pCgp.

[0190] INXN-2004 lentiviral vector

[0191] IGE308 LV-COL7 vector transfer plasmid

[0192] The IGE308 plasmid was constructed using standard molecular cloning methods. The construction process included cloning the human COL7A1 gene and introducing the cloned COL7A1 gene into the lentiviral vector (SIN) backbone pFUGW to generate the IGE308 LV-COL7 vector transfer plasmid. ...

example 3

[0273] Example 3: Training runs 8, 9 and 10 and enhanced enzymatic digestion of biopsies

[0274] Training Run 8 and Enhanced Enzymatic Digestion of Biopsies

[0275] In the TR mentioned above, it was suspected that the biopsy digestion method could not achieve efficient digestion of biopsy tissue with a size of 3-4 mm. In TR8, the application of additional shear forces during digestion was incorporated into the process to increase overall digestion efficiency. The digestion procedure was modified as follows: every 15 ± 2 minutes during digestion, pulse vortex the centrifuge tube for 5 seconds at the maximum setting, returning the centrifuge tube to the orbital shaker after each vortex; end the incubation at 60 minutes , pulse vortex the centrifuge tube for 10 seconds at the maximum setting.

[0276]Biopsies from RDEB donors were processed and digested using the enhanced digestion method. Cells from the digestion were seeded into T-75 flasks using medium supplemented with G...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to self-inactivating lentiviral vectors comprising the COL7A1 gene or a functional variant thereof and its use in a method for the treatment of Type VII collagen deficiency, such as dominant dystrophic epidermolysis and recessive dystrophic epidermolysis.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 9, 2017, is named 0100-0016PR1_SL.txt and is 92,924 bytes in size. technical field [0003] The present invention relates to compositions and methods for the treatment of type VII collagen deficiency, such as dystrophic epidermolysis bullosa, comprising administering an autologous genetically modified cells. Background technique [0004] Collagen type VII (C7) is a protein important for anchoring fibril formation at the dermal-epidermal junction (DEJ), which holds multiple skin layers together (Burgeson 1993; Leigh et al. 1988). Dystrophic epidermolysis bullosa (DEB) is a genetic disorder characterized by C7 deficiency that results in damage to the anchoring fibrils that attach between the epidermis and the underlying dermis, thereby affecting the skin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/17A61K38/39C12N15/87
CPCA61K35/33A61K35/36C12N5/0629C12N15/86C12N5/0625C12N2510/00C12N2740/16043C12N2740/16052A61K38/39A61P17/00A61L27/52A61L27/24C12N5/0656A61K9/0019A61L27/227A61K48/005
Inventor 弗农·戴利马里恩·恰基亚斯张树源约翰·马斯洛斯基安娜·马尔亚拉
Owner INTREXON CORP (US)